clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Stomach Diseases D013272 7 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Synovitis D013585 15 associated lipids
Syphilis D013587 6 associated lipids
Tenosynovitis D013717 3 associated lipids
Tooth Discoloration D014075 7 associated lipids
Tuberculosis D014376 20 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Typhoid Fever D014435 2 associated lipids
Ureteral Diseases D014515 3 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Urethritis D014526 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urination Disorders D014555 9 associated lipids
Urticaria D014581 13 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Mosdósi B et al. Severe acrocyanosis precipitated by cold agglutinin secondary to infection with Mycoplasma pneumoniae in a pediatric patient. 2017 Croat. Med. J. pmid:29308834
Zhang X and Hu C Selecting optimal columns for clarithromycin impurity analysis according to the quantitative relationship of hydrophobic subtraction model. 2017 J Pharm Biomed Anal pmid:28024686
Addo KK et al. Genotyping and drug susceptibility testing of mycobacterial isolates from population-based tuberculosis prevalence survey in Ghana. 2017 BMC Infect. Dis. pmid:29197331
Liu W et al. Rapid detection of mutations in erm(41) and rrl associated with clarithromycin resistance in Mycobacterium abscessus complex by denaturing gradient gel electrophoresis. 2017 J. Microbiol. Methods pmid:29079298
Chang CH et al. Non-Tuberculous Mycobacteria Infection Following Autologous Fat Grafting on the Face. 2017 Aesthet Surg J pmid:29045552
Yang YJ et al. Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes. 2017 Ann. Med. pmid:28266875
Geng X et al. The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. 2017 Antimicrob. Agents Chemother. pmid:28242673
Larsen EL et al. Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials. 2017 Br J Clin Pharmacol pmid:28185274
Ono S et al. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. 2017 Helicobacter pmid:28098408
Gouin-Thibault I et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. 2017 J. Thromb. Haemost. pmid:27893182
Park J et al. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. 2017 Clin. Infect. Dis. pmid:28011609
Park SM et al. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. 2017 J. Gastroenterol. Hepatol. pmid:27505301
Ishiguro N et al. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. 2017 PLoS ONE pmid:28288170
Attaran B et al. Effect of biofilm formation by clinical isolates of on the efflux-mediated resistance to commonly used antibiotics. 2017 World J. Gastroenterol. pmid:28275296
Yoon H et al. Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis. 2017 Gut Liver pmid:27282269
Shah SA et al. Clarithromycin inhibits TNF-α-induced MUC5AC mucin gene expression via the MKP-1-p38MAPK-dependent pathway. 2017 Int. Immunopharmacol. pmid:28550735
Osaki T et al. Usefulness of detection of clarithromycin-resistant Helicobacter pylori from fecal specimens for young adults treated with eradication therapy. 2017 Helicobacter pmid:28544222
Chang CT et al. Antibiotic treatment of zebrafish mycobacteriosis: tolerance and efficacy of treatments with tigecycline and clarithromycin. 2017 J. Fish Dis. pmid:28422304
Furuya H et al. SAPHO syndrome-like presentation of disseminated nontuberculous mycobacterial infection in a case with neutralizing anti-IFNγ autoantibody. 2017 Rheumatology (Oxford) pmid:28371927
Lee H et al. Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial. 2017 Trials pmid:29149904
Ye JF et al. Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication. 2017 J Dig Dis pmid:29119724
Sotto RB et al. Sub-lethal pharmaceutical hazard tracking in adult zebrafish using untargeted LC-MS environmental metabolomics. 2017 J. Hazard. Mater. pmid:28623724
Liatsos C and Leontiadis GII The "report card" to grade H. Pylori treatment regimens: is it achievable in real-world in areas with high clarithromycin resistance? 2017 J Gastrointestin Liver Dis pmid:28617893
Chew CA et al. The diagnosis and management of H. pylori infection in Singapore. 2017 Singapore Med J pmid:28536725
Moon SH et al. Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin. 2017 J. Med. Chem. pmid:29136469
Carneiro MDS et al. Lack of association between rrl and erm(41) mutations and clarithromycin resistance in Mycobacterium abscessus complex. 2017 Mem. Inst. Oswaldo Cruz pmid:29091138
Oikawa R et al. Enrichment of Helicobacter pylori mutant strains after eradication therapy analyzed by gastric wash-based quantitative pyrosequencing. 2017 Tumour Biol. pmid:28990461
Feng L et al. Removal of antibiotics during the anaerobic digestion of pig manure. 2017 Sci. Total Environ. pmid:28628813
Mougari F et al. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. 2017 J. Antimicrob. Chemother. pmid:28333340
Anwar HF et al. Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. 2017 Bioorg. Med. Chem. pmid:28302508
Gisbert JP Helicobacter pylori-related diseases. 2016 Gastroenterol Hepatol pmid:27888863
Orrin E et al. Sporotrichoid Mycobacterium chelonae. 2016 Australas. J. Dermatol. pmid:27469486
Yamamoto K et al. Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3. 2016 Pharmacol. Res. pmid:27468646
Ferro BE et al. Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. 2016 Antimicrob. Agents Chemother. pmid:27458221
Patton PH et al. Anti-tuberculous therapy for maintenance of remission in Crohn's disease. 2016 Cochrane Database Syst Rev pmid:27444319
Kuo CH et al. A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. 2016 Medicine (Baltimore) pmid:27227911
Sluch IM et al. Mycobacterium chelonae Scleral Abscess After Intravitreal Ranibizumab Injection. 2016 Cornea pmid:27227391
Xu J et al. Preparation, characterization and pharmacokinetics evaluation of clarithromycin-loaded Eudragit(®) L-100 microspheres. 2016 Eur J Drug Metab Pharmacokinet pmid:25652786
Buchicchio A et al. Biodegradation of carbamazepine and clarithromycin by Trichoderma harzianum and Pleurotus ostreatus investigated by liquid chromatography - high-resolution tandem mass spectrometry (FTICR MS-IRMPD). 2016 Sci. Total Environ. pmid:27039063
Melia MT and Auwaerter PG Time for a Different Approach to Lyme Disease and Long-Term Symptoms. 2016 N. Engl. J. Med. pmid:27028918
Berende A et al. Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. 2016 N. Engl. J. Med. pmid:27028911
Belz D et al. Mycobacterium marinum infection initially diagnosed as metastatic Crohn's disease. 2016 J Eur Acad Dermatol Venereol pmid:25510444
Niv Y Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. 2016 Digestion pmid:26849820
Song Z et al. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. 2016 Dig Liver Dis pmid:26847964
Vannarath S et al. Antibiotic Resistant Pattern of Helicobacter Pylori Infection Based on Molecular Tests in Laos. 2016 Asian Pac. J. Cancer Prev. pmid:26838225
Konstantinidis T et al. Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps. 2016 Antimicrob. Agents Chemother. pmid:26643338
Wu TS et al. Postcesarean section wound infection caused by Mycobacterium massiliense. 2016 J Microbiol Immunol Infect pmid:26350122
Senatore FJ et al. Helicobacter pylori treatment: Still a work in progress. 2016 Postgrad Med pmid:26490697
Narita M et al. Antimicrobial Susceptibility of Microorganisms Isolated from Periapical Periodontitis Lesions. 2016 Bull. Tokyo Dent. Coll. pmid:27665691
Ghaith D et al. Mutations affecting domain V of the 23S rRNA gene in Helicobacter pylori from Cairo, Egypt. 2016 J Chemother pmid:26358218